本研究由重庆市卫生健康委员会和重庆市科学技术局联合开展的医学研究重点项目（2022ZDXM037）、武汉市卫生健康委员会中医药科研基金重点项目（WZ22A03）和重庆市自然科学基金（cstc2020jcyj-msxmX0592）提供资金支持。

所有涉及人类参与者的研究程序均符合重庆市中医院伦理委员会的伦理标准和《赫尔辛基宣言》（1964年）及其后续修正案的原则，并已获得上述伦理委员会的批准。图像数据收集是在患者的口头和书面同意下进行的，并且作为检查的常规部分，为教学目的拍摄的照片是使用多光谱皮肤镜获得的。
1. 患者选择
<ol><li>设置以下纳入标准5:<ol><li>根据面部浅色至深棕色、边界明确的斑块的存在来选择患者，通常具有对称分布、无炎症和脱屑。</li>
		<li>根据是否存在明显的主观症状（如瘙痒、灼热和疼痛）来选择患者。</li>
		<li>考虑到黄褐斑主要发生在女性身上，主要是在青春期之后，选择患者。</li>
		<li>在选择患者时，应考虑病情的季节性变化 - 通常在夏季更严重，在冬季较温和。</li>
		<li>如果存在可能导致色素沉着过度的其他疾病（如颧颧梭蓝痣、Riehl 黑变病和色素性日光性皮炎），则排除患者。</li>
	</ol></li>
</ol>2.滚筒微针治疗的准备工作
<ol><li>术前沟通<ol><li>了解患者的治疗目标和美容愿望，并收集完整的病史，包括用药史、过敏史、禁忌症和过去的美容治疗。</li>
		<li>告知患者治疗的效果、步骤、潜在并发症、恢复时间、持续时间和费用。讨论具体的治疗计划和替代方案，以确保所有患者的疑问都得到解决，帮助他们建立切合实际的期望并实现更高的满意度。</li>
		<li>要求患者签署知情同意书。</li>
	</ol></li>
	<li>环境要求<ol><li>留出一个安静、光线充足的治疗室用于操作滚筒微针，并在手术前用紫外线消毒 30 分钟。</li>
		<li>要求患者在进入治疗室时戴上鞋套和帽子。</li>
	</ol></li>
	<li>准备治疗所需的物品和药物<ol><li>检查并准备 物料清单中列出的所有材料。</li>
	</ol></li>
	<li>卸妆和清洁<ol><li>如果治疗区域被化妆品覆盖，请在清洁前用卸妆液彻底卸妆。</li>
		<li>对于不化妆的人，请用温和的清洁产品清洁治疗区域。</li>
	</ol></li>
	<li>多光谱皮肤镜检查记录 注意: 多光谱皮肤镜使用不同的光源来捕捉面部超高像素图像。<ol><li>治疗前和三次治疗后，使用多光谱皮肤镜从三个不同角度拍摄患者的前部、左侧（45°）和右侧（45°）的照片，并记录患者的紫外线浅层和深层斑点和褐色斑点的值</li>
	</ol></li>
	<li>局部麻醉的应用<ol><li>将5%利多卡因乳膏均匀涂抹在治疗区域，总剂量为30-40g，并用保鲜膜包裹以增强麻醉效果40-60分钟。 注意:一些患者可能会表现出对局部麻醉剂过敏的症状。患者可能会在应用部位出现严重的瘙痒、灼热或刺痛。如果发生此类反应，请立即移除麻醉剂并提供适当的对症治疗。</li>
		<li>在下次治疗之前，请确保在麻醉应用区域对皮肤进行适当的滋润。</li>
	</ol></li>
	<li>微针溶液的制备<ol><li>使用注射器提取 5 mL 5% 氨甲环酸溶液，并将其放在一边使用。</li>
	</ol></li>
	<li>微针器械的制备<ol><li>选择0.5mm滚筒微针（图1），并将其浸泡在0.1%苯扎溴铵溶液中约20分钟以消毒。</li>
		<li>用生理盐水冲洗微针 3 次以去除消毒剂。 注意:通过为每个患者使用单个滚筒微针来避免交叉污染，以防止由于钝针而对皮肤造成不必要的伤害，并防止疾病在患者之间传播。</li>
	</ol></li>
	<li>去除局部麻醉<ol><li>在局部麻醉应用足够长的时间后，取下保鲜膜并用刮刀刮掉麻醉剂。使用浸泡在0.9%生理盐水溶液中的纱布擦去面部残留的麻醉剂。</li>
	</ol></li>
	<li>消毒<ol><li>露出治疗区域，治疗面部时用消毒毛巾包裹头发，用0.1%苯扎溴铵棉球从顶部到发际线边缘，到下颌边缘和下巴3次消毒面部皮肤，遵循"自下而上，向内向外"的原则，防止感染。</li>
	</ol></li>
</ol>3. 滚筒微针手术
<ol><li>让治疗师洗手，戴上帽子、口罩和无菌手套。</li>
	<li>在告知患者开始手术后，指导患者闭上眼睛，按照左脸颊、右脸颊、前额、下巴、上唇和鼻子的顺序进行治疗。用注射器将适量氨甲环酸溶液注射到皮肤上，用手均匀涂抹，然后用生理盐水冲洗滚筒微针，在治疗区域沿水平、垂直、倾斜方向短距离滚动。</li>
	<li>逐渐在不同区域进行治疗，在滚动时涂抹溶液以增强吸收。在一个区域重复 3-5 次，最好是皮肤潮红且没有明显出血。均匀地用力，不要太重也不要太轻，不要用微针在皮肤上拖动。</li>
</ol>4.功效评价
<ol><li>使用滚筒微针和局部氨甲环酸溶液的组合 3 次治疗黄褐斑，每 4 周一次，作为一个疗程。</li>
	<li>治疗前后使用多光谱皮肤镜，3x，根据患者紫外线浅深斑点和褐色斑点的值观察疗效。值越小，黄褐斑越轻。</li>
	<li>统计分析处理前后UV浅层和深层斑点以及褐色斑点的变化。</li>
</ol>

用氨甲环酸和微针疗法加强黄褐斑治疗

<ol><li>Passeron, T., Picardo, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Melasma%2C+a+photoaging+disorder%5BTitle%5D)+AND+%22Pigment+Cell+%26+Melanoma+Research%22%5BJournal%5D)">Melasma, a photoaging disorder.</a> Pigment Cell & Melanoma Research. 31 (4), 461-465 (2018).</li>
<li>Pigment Disease Group. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dermatovenereology+Professional+Committee+of+Chinese+Society+of+Integrative+Medicine%2C+Vitiligo+Research+Center+of+the+Dermatology+and+Venereal+Disease+Branch+of+the+Chinese+Medical+Association%2C+Pigment+Disease+Working+Group+of+the+Dermatology+and+Venereal+Disease+Branch+of+the+Chinese+Medical+Association%2C+Chinese+Medical+Doctor+Association.+Consensus+on+diagnosis+and+treatment+of+melasma+in+China+%282021+vision%29%5BTitle%5D)+AND+%22Chinese+Journal+Dermatology%22%5BJournal%5D)">Dermatovenereology Professional Committee of Chinese Society of Integrative Medicine, Vitiligo Research Center of the Dermatology and Venereal Disease Branch of the Chinese Medical Association, Pigment Disease Working Group of the Dermatology and Venereal Disease Branch of the Chinese Medical Association, Chinese Medical Doctor Association. Consensus on diagnosis and treatment of melasma in China (2021 vision).</a> Chinese Journal Dermatology. 54 (2), 110-115 (2021).</li>
<li>Vineet, K. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microneedle+arrays+for+cutaneous+and+transcutaneous+drug+delivery%2C+disease+diagnosis%2C+and+cosmetic+aid%5BTitle%5D)+AND+%22Journal+of+Drug+Delivery+Science+and+Technology%22%5BJournal%5D)">Microneedle arrays for cutaneous and transcutaneous drug delivery, disease diagnosis, and cosmetic aid.</a> Journal of Drug Delivery Science and Technology. 79, 104058(2023).</li>
<li>Skin Laser Medical Aesthetics Group, Dermatology and Venereology Branch, Chinese Medical Association, Skin Laser Technology Application Research Center of the Chinese Medical Association. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chinese+dermatologists%27+consensus+on+laser+and+IPLS+treatment+and+skin+repairment+of+melasma%5BTitle%5D)+AND+%22Journal+Practical+Dermatology%22%5BJournal%5D)">Chinese dermatologists' consensus on laser and IPLS treatment and skin repairment of melasma.</a> Journal Practical Dermatology. 13 (2), 65-69 (2020).</li>
<li>Pigment Disease Group. Dermatovenereology Professional Committee of Chinese Society of Integrative Medicine. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Clinical+diagnosis+and+efficacy+criteria+for+melasma+%28revised+in+2003%29%5BTitle%5D)+AND+%22Chinese+Journal+of+Dermatology+Venereology+Integrative+Traditional+and+Western+Medicine%22%5BJournal%5D)">Clinical diagnosis and efficacy criteria for melasma (revised in 2003).</a> Chinese Journal of Dermatology Venereology Integrative Traditional and Western Medicine. 3 (1), 66(2004).</li>
<li>McKesey, J., Tovar-Garza, A., Pandya, A. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Melasma+treatment%3A+an+evidence-based+review%5BTitle%5D)+AND+%22American+Journal+of+Clinical+Dermatology%22%5BJournal%5D)">Melasma treatment: an evidence-based review.</a> American Journal of Clinical Dermatology. 21 (2), 173-225 (2020).</li>
<li>Budamakuntla, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+randomised%2C+open-label%2C+comparative+study+of+tranexamic+acid+microinjections+and+tranexamic+acid+with+microneedling+in+patients+with+melasma%5BTitle%5D)+AND+%22Journal+of+Cutaneous+and+Aesthetic+Surgery%22%5BJournal%5D)">A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma.</a> Journal of Cutaneous and Aesthetic Surgery. 6 (3), 139-143 (2013).</li>
<li>Cohen, B. E., Elbuluk, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microneedling+in+skin+of+color%3A+a+review+of+uses+and+efficacy%5BTitle%5D)+AND+%22Journal+of+the+American+Academy+of+Dermatology%22%5BJournal%5D)">Microneedling in skin of color: a review of uses and efficacy.</a> Journal of the American Academy of Dermatology. 74 (2), 348-355 (2016).</li>
<li>Lee, H. C., Thng, T. G. S., Goh, C. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Oral+tranexamic+acid+%28TA%29+in+the+treatment+of+melasma%3A+a+retrospective+analysis%5BTitle%5D)+AND+%22Journal+of+the+American+Academy+of+Dermatology%22%5BJournal%5D)">Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis.</a> Journal of the American Academy of Dermatology. 75 (2), 385-392 (2016).</li>
<li>Banihashemi, M., Zabolinejad, N., Jaafari, M. R., Salehi, M., Jabari, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Comparison+of+therapeutic+effects+of+liposomal+tranexamic+acid+and+conventional+hydroquinone+on+melasma%5BTitle%5D)+AND+%22Journal+of+Cosmetic+Dermatology%22%5BJournal%5D)">Comparison of therapeutic effects of liposomal tranexamic acid and conventional hydroquinone on melasma.</a> Journal of Cosmetic Dermatology. 14 (3), 174-177 (2015).</li>
<li>Ebrahimi, B., Naeini, F. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Topical+tranexamic+acid+as+a+promising+treatment+for+melasma%5BTitle%5D)+AND+%22Journal+of+Research+in+Medical+Sciences%22%5BJournal%5D)">Topical tranexamic acid as a promising treatment for melasma.</a> Journal of Research in Medical Sciences. 19 (8), 753-757 (2014).</li>
<li>Na, J. I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effect+of+tranexamic+acid+on+melasma%3A+a+clinical+trial+with+histological+evaluation%5BTitle%5D)+AND+%22Journal+of+the+European+Academy+of+Dermatology+and+Venereology%22%5BJournal%5D)">Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.</a> Journal of the European Academy of Dermatology and Venereology. 27 (8), 1035-1039 (2013).</li>
<li>Kim, E. H., Kim, Y. C., Lee, E. S., Kang, H. Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+vascular+characteristics+of+melasma%5BTitle%5D)+AND+%22Journal+of+Dermatological+Science%22%5BJournal%5D)">The vascular characteristics of melasma.</a> Journal of Dermatological Science. 46 (2), 111-116 (2007).</li>
<li>Yuan, C., Wang, X. M., Yang, L. J., Wu, P. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tranexamic+acid+accelerates+skin+barrier+recovery+and+upregulates+occluding+in+damaged+skin%5BTitle%5D)+AND+%22International+Journal+of+Dermatology%22%5BJournal%5D)">Tranexamic acid accelerates skin barrier recovery and upregulates occluding in damaged skin.</a> International Journal of Dermatology. 53 (8), 959-965 (2014).</li>
<li>Tohgasaki, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enolase-1+expression+in+the+stratum+corneum+is+elevated+with+parakeratosis+of+atopic+dermatitis+and+disrupts+the+cellular+tight+junction+barrier+in+keratinocytes%5BTitle%5D)+AND+%22International+Journal+of+Cosmetic+Science%22%5BJournal%5D)">Enolase-1 expression in the stratum corneum is elevated with parakeratosis of atopic dermatitis and disrupts the cellular tight junction barrier in keratinocytes.</a> International Journal of Cosmetic Science. 40 (2), 178-186 (2018).</li>
<li>Lima, E. V. A., Lima, M. M. D. A., Paixão, M. P., Miot, H. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Assessment+of+the+effects+of+skin+microneedling+as+adjuvant+therapy+for+facial+melasma%3A+a+pilot+study%5BTitle%5D)+AND+%22BMC+Dermatology%22%5BJournal%5D)">Assessment of the effects of skin microneedling as adjuvant therapy for facial melasma: a pilot study.</a> BMC Dermatology. 17 (1), 14(2017).</li>
<li>Saleh, F., Abdel-Azim, E., Ragaie, M., Guendy, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Topical+tranexamic+acid+with+microneedling+versus+microneedling+alone+in+treatment+of+melasma%3A+clinical%2C+histopathologic%2C+and+immunohistochemical+study%5BTitle%5D)+AND+%22Journal+of+Egypt+Women%27s+Dermatologic+Society%22%5BJournal%5D)">Topical tranexamic acid with microneedling versus microneedling alone in treatment of melasma: clinical, histopathologic, and immunohistochemical study.</a> Journal of Egypt Women's Dermatologic Society. 16 (2), 89(2019).</li>
<li>Bailey, A. J. M., Li, H. O., Tan, M. G., Cheng, W., Dover, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microneedling+as+an+adjuvant+to+topical+therapies+for+melasma%3A+A+systematic+review+and+meta-analysis%5BTitle%5D)+AND+%22Journal+of+the+American+Academy+of+Dermatology%22%5BJournal%5D)">Microneedling as an adjuvant to topical therapies for melasma: A systematic review and meta-analysis.</a> Journal of the American Academy of Dermatology. 86 (4), 797-810 (2022).</li>
</ol>

提交人无需声明任何利益冲突。

黄褐斑的发病机制复杂，治疗方法包括全身用药、局部脱色剂、化学换肤和激光疗法。不幸的是，没有一种治疗方法对所有患者都普遍有效，不能总是保证满意的结果6.光疗治疗黄褐斑呈下降趋势，部分患者在光疗后黄褐斑恶化。这是由于炎症性黄褐斑中皮肤敏感和皮肤屏障功能受损的个体增加。针对黑色素的激光或其他治疗可能会加剧皮肤的炎症反应，导致黄褐斑症状加重。?...

黄褐斑，也称为黄褐斑，是一种慢性和获得性面部色素沉着过度的皮肤病。临床上，它表现为对称的浅棕色至深棕色斑块，边界不清晰，分布在脸颊、前额和下颌线。亚洲育龄妇女的发病率可高达 30%1。这种疾病很容易诊断，但很难治愈。黄褐斑的发病机制尚不完全清楚，但有三个主要因素促成了黄褐斑的发展:遗传易感性、暴露在阳光下和荷尔蒙变化。黑色素合成增加、皮肤病变部位的血管增生、炎症反应和皮肤屏障功能受损都在黄褐斑2 的发生中起作用。
目前，黄褐斑的治疗选择包括激光疗法和药物治疗，其中透皮给药是一种广泛使用的方法。然而，主要的挑战在于角质层的屏障功能，它阻碍了药物的渗透。微针疗法在短时间内在皮肤中产生多个微通道，破坏角质层，诱导胶原蛋白的产生，并增加皮肤的通透性。这种方法有望使药物扩散到皮肤中，然后迅速重新封闭，从而避免引入有毒或刺激性物质3.
常用的微针工具包括电子水光注射微针、滚筒微针、电助纳米晶微针、梅花微针和单针微针4。滚筒式微针的特点是创伤小，疗效好，操作方便，可以与其他一些药物合用治疗黄褐斑。对黄褐斑具有良好的治疗前景，在临床上值得进一步推广和使用。本文介绍了滚筒微针联合氨甲环酸治疗黄褐斑的操作和注意事项，并通过临床案例论证了滚筒微针联合氨甲环酸治疗黄褐斑的疗效。

<table><tbody><tr><td>5 mL syringe</td><td></td><td></td><td></td></tr><tr><td>Benzalkonium bromide solution</td><td>Chongqing Traditional Chinese Medicine Hospital</td><td>H20050531</td><td>0.1%</td></tr><tr><td>cling film</td><td></td><td></td><td></td></tr><tr><td>Compound lidocaine cream</td><td>Beijing Ziguang Pharmaceutical Co., Ltd.</td><td>H20063466</td><td>5.0%</td></tr><tr><td>disinfectant towel</td><td></td><td></td><td></td></tr><tr><td>disposable curved disc</td><td></td><td></td><td></td></tr><tr><td>Multispectral Dermoscope</td><td>CBS Medical Skin Analysis, Wuhan, China</td><td>CBS-2022</td><td></td></tr><tr><td>Roller microneedle</td><td>Guangzhou Yuanxiang Biotechnology Co., Ltd</td><td>221001</td><td>(model: 0.22 x 0.5 mm, Figure 1)</td></tr><tr><td>Sodium chloride solution</td><td>Hubei Tiansheng Pharmaceutical Co., Ltd.</td><td>H42021838</td><td>0.9%</td></tr><tr><td>sterile cotton swab</td><td></td><td></td><td></td></tr><tr><td>sterile gauze</td><td></td><td></td><td></td></tr><tr><td>sterile gloves</td><td></td><td></td><td></td></tr><tr><td>tongue depressor</td><td></td><td></td><td></td></tr><tr><td>Tranexamic acid solution</td><td>Shanghai Hyundai Hasen (Shangqiu) Pharmaceutical Co., Ltd.</td><td>H20184047</td><td>5.0%</td></tr><tr><td>treatment vehicle</td><td></td><td></td><td></td></tr></tbody></table>

roller microneedle combined with tranexamic acid solution in treating melasma

黄褐斑是一种常见的获得性面部色素沉着性皮肤病，临床诊断简单明了，但在有效管理方面存在挑战。黄褐斑的确切根本原因仍然难以捉摸，目前的治疗方法主要包括药物和激光干预，疗效有限。透皮给药是黄褐斑的一种普遍治疗方法，通常通过使用微针来促进。其中，氨甲环酸作为一种常用的治疗剂出现。微针的一个子集，称为滚筒微针，在这种方法中发挥着重要作用，它用多根细针巧妙地刺穿表皮，与药物输送协同作用。这种方法不仅可以增强药物吸收，还可以提高治疗效果，同时最大限度地减少组织创伤。这些特性预示着治疗黄褐斑的有希望的途径。本文主要介绍滚筒微针和氨甲环酸溶液联合治疗黄褐斑的情况，并通过临床案例论证了滚筒微针和氨甲环酸溶液治疗黄褐斑的疗效。

病例1为57岁女性，有10年病史，选取治疗及疗效评价。在治疗前和三个治疗疗程（图 2、 Figure 3 和 Figure 4）后评估滚筒微针和氨甲环酸溶液组合的疗效，并使用多光谱皮肤镜从不同角度观察。在正面视图中，紫外线浅斑点、紫外线深点和棕色区域分别减少了 35.91 mm2、163.32 mm2 和 82.4 mm2 。在45°的右侧视图中...

Watch this Scientific Journal Video about Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma at JoVE.com

作者聚焦: 黄褐斑的非手术治疗 – 氨甲环酸微针

本文提出了一种通过使用滚筒微针结合氨甲环酸溶液进行黄褐斑治疗的方案，并评估疗效。

滚筒微针联合氨甲环酸溶液治疗黄褐斑

Melasma, a common, acquired facial pigmentation skin disorder, presents a straightforward clinical diagnosis but poses challenges in terms of effective ...

我们的研究重点是色素性疾病的非手术治疗。我们测试了滚筒微针联合氨甲环酸溶液治疗黄褐斑的疗效。我们将研究使用滚筒微针和氨甲环酸溶液组合治疗黄褐斑的有效性和最大难易程度。

roller-microneedle-combined-with-tranexamic-acid-solution-treating

Research

JoVE Journal

Medicine

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

937 次观看.  Chongqing Hospital of Traditional Chinese Medicine. 我们的研究重点是色素性疾病的非手术治疗。我们测试了滚筒微针联合氨甲环酸溶液治疗黄褐斑的疗效。我们将研究使用滚筒微针和氨甲环酸溶液组合治疗黄褐斑的有效性和最大难易程度。

视频: 作者聚焦: 黄褐斑的非手术治疗 – 氨甲环酸微针

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Cutaneous melanoma is well known as the most aggressive skin cancer. Although the risk factors and major genetic alterations continue to be documented with increasing depth, the incidence rate of cutaneous melanoma has shown a rapid and continuous increase during recent decades. In order to find effective preventative methods, it is important to understand the early steps of melanoma initiation in the skin. Previous data has demonstrated that follicular melanocyte stem cells (MCSCs) in the adult skin tissues can act as melanoma cells of origin when expressing oncogenic mutations and genetic alterations. Tumorigenesis arising from melanoma-prone MCSCs can be induced when MCSCs transition from a quiescent to active state. This transition in melanoma-prone MCSCs can be promoted by the modulation of either hair follicle stem cells&#39; activity state or through extrinsic environmental factors such as ultraviolet-B (UV-B). These factors can be artificially manipulated in the laboratory by chemical depilation, which causes transition of hair follicle stem cells and MCSCs from a quiescent to active state, and by UV-B exposure using a benchtop light. These methods provide successful spatial and temporal control of cutaneous melanoma initiation in the murine dorsal skin. Therefore, these in vivo model systems will be valuable to define the early steps of cutaneous melanoma initiation and could be used to test potential methods for tumor prevention.

The following procedure describes a method for spatial and temporal control of melanocytic tumor initiation in murine dorsal skin, using a genetically engineered mouse model. This protocol describes macroscopic as well as microscopic cutaneous melanoma initiation.

突变黑色素细胞干细胞引发小鼠黑色素瘤的时空控制

Cutaneous melanoma is well known as the most aggressive skin cancer. Although the risk factors and major genetic alterations continue to be documented ...

科研

癌症研究

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Fairness of skin, UV sensitivity and skin cancer risk all correlate with the physiologic function of the melanocortin 1 receptor, a Gs-coupled signaling protein found on the surface of melanocytes. Mc1r stimulates adenylyl cyclase and cAMP production which, in turn, up-regulates melanocytic production of melanin in the skin. In order to study the mechanisms by which Mc1r signaling protects the skin against UV injury, this study relies on a mouse model with "humanized skin" based on epidermal expression of stem cell factor (Scf). K14-Scf transgenic mice retain melanocytes in the epidermis and therefore have the ability to deposit melanin in the epidermis. In this animal model, wild type Mc1r status results in robust deposition of black eumelanin pigment and a UV-protected phenotype. In contrast, K14-Scf animals with defective Mc1r signaling ability exhibit a red/blonde pigmentation, very little eumelanin in the skin and a UV-sensitive phenotype. Reasoning that eumelanin deposition might be enhanced by topical agents that mimic Mc1r signaling, we found that direct application of forskolin extract to the skin of Mc1r-defective fair-skinned mice resulted in robust eumelanin induction and UV protection 1. Here we describe the method for preparing and applying a forskolin-containing natural root extract to K14-Scf fair-skinned mice and report a method for measuring UV sensitivity by determining minimal erythematous dose (MED). Using this animal model, it is possible to study how epidermal cAMP induction and melanization of the skin affect physiologic responses to UV exposure.

Epidermal melanin is induced by topical application of forskolin in a murine model of the fair-skinned UV-sensitive human. Pharmacologic manipulation of cAMP levels in the skin and epidermal darkening strongly protect against UV-mediated inflammation (sunburn) as measured by the minimum erythematous dose (MED) assay.

表皮黑色素和防止晒斑的人性化小鼠模型的诱导药物

Fairness of skin, UV sensitivity and skin cancer  risk all correlate with the physiologic function of the melanocortin 1  receptor, a Gs-coupled signaling ...

医学

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

A novel device that employs TTF therapy has recently been developed and is currently in use for the treatment of recurrent glioblastoma (rGBM). It was FDA approved in April 2011 for the treatment of patients 22 years or older with rGBM. The device delivers alternating electric fields and is programmed to ensure maximal tumor cell kill1.
Glioblastoma is the most common type of glioma and has an estimated incidence of approximately 10,000 new cases per year in the United States alone2. This tumor is particularly resistant to treatment and is uniformly fatal especially in the recurrent setting3-5. Prior to the approval of the TTF System, the only FDA approved treatment for rGBM was bevacizumab6. Bevacizumab is a humanized monoclonal antibody targeted against the vascular endothelial growth factor (VEGF) protein that drives tumor angiogenesis7. By blocking the VEGF pathway, bevacizumab can result in a significant radiographic response (pseudoresponse), improve progression free survival and reduce corticosteroid requirements in rGBM patients8,9. Bevacizumab however failed to prolong overall survival in a recent phase III trial26. A pivotal phase III trial (EF-11) demonstrated comparable overall survival between physicians&#8217; choice chemotherapy and TTF Therapy but better quality of life were observed in the TTF arm10.
There is currently an unmet need to develop novel approaches designed to prolong overall survival and/or improve quality of life in this unfortunate patient population. One appealing approach would be to combine the two currently approved treatment modalities namely bevacizumab and TTF Therapy. These two treatments are currently approved as monotherapy11,12, but their combination has never been evaluated in a clinical trial. We have developed an approach for combining those two treatment modalities and treated 2 rGBM patients. Here we describe a detailed methodology outlining this novel treatment protocol and present representative data from one of the treated patients.

A novel methodology that is employed for the treatment of recurrent glioblastomas is described. This treatment approach employs the application of alternating electric tumor treating fields (TTFields), known as TTF Therapy in combination with bevacizumab, a targeted agent that is currently FDA approved as monotherapy.

肿瘤治疗领域的治疗与联合贝伐单抗治疗复发性胶质母细胞瘤的治疗

A novel device that employs TTF therapy has recently been developed and is currently in use for the treatment of recurrent glioblastoma (rGBM). It was FDA ...

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Mitochondrial dysfunction plays a significant role in the aging process and in neurodegenerative diseases including several hereditary spinocerebellar ataxias and other movement disorders marked by progressive degeneration of the cerebellum. The goal of this protocol is to assess mitochondrial dysfunction in Spinocerebellar ataxia type 1 (SCA1) and assess the efficacy of pharmacological targeting of metabolic respiration via the water-soluble compound succinic acid to slow disease progression. This approach is applicable to other cerebellar diseases and can be adapted to a host of water-soluble therapies.
Ex vivo analysis of mitochondrial respiration is used to detect and quantify disease-related changes in mitochondrial function. With genetic evidence (unpublished data) and proteomic evidence of mitochondrial dysfunction in the SCA1 mouse model, we evaluate the efficacy of treatment with the water-soluble metabolic booster succinic acid by dissolving this compound directly into the home cage drinking water. The ability of the drug to pass the blood brain barrier can be deduced using high performance liquid chromatography (HPLC). The efficacy of these compounds can then be tested using multiple behavioral paradigms including the accelerating rotarod, balance beam test and footprint analysis. Cytoarchitectural integrity of the cerebellum can be assessed using immunofluorescence assays that detect Purkinje cell nuclei and Purkinje cell dendrites and soma. These methods are robust techniques for determining mitochondrial dysfunction and the efficacy of treatment with water-soluble compounds in cerebellar neurodegenerative disease.

We present a biochemical and behavioral protocol to evaluate the efficacy of mitochondria-targeted water-soluble compounds for the treatment of Spinocerebellar ataxia type 1 (SCA1) and other cerebellar neurodegenerative diseases.

治疗SCA1小鼠水溶性化合物，以非特异性升压线粒体功能

Mitochondrial dysfunction plays a significant role in the aging process and in neurodegenerative diseases including several hereditary spinocerebellar ...

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Self-assembling peptides (SAPs) are promising vehicles for the delivery of hydrophobic therapeutics for clinical applications; their amphipathic properties allow them to dissolve hydrophobic compounds in the aqueous environment of the human body. However, self-assembling peptide solutions have poor blood compatibility (e.g., low osmolarity), hindering their clinical application through intravenous administrations. We have recently developed a generalized platform for hydrophobic drug delivery, which combines SAPs with amino acid solutions (SAP-AA) to enhance drug solubility and increase formulation osmolarity to reach the requirements for clinical uses. This formulation strategy was thoroughly tested in the context of three structurally different hydrophobic compounds &#8211; PP2, rottlerin, and curcumin &#8211; in order to demonstrate its versatility. Furthermore, we examined effects of changing formulation components by analyzing 6 different SAPs, 20 naturally existing amino acids at low and high concentrations, and two different co-solvents dimethyl sulfoxide (DMSO) and ethanol. Our strategy proved to be effective in optimizing components for a given hydrophobic drug, and therapeutic function of the formulated inhibitor, PP2, was observed both in vitro and in vivo. This manuscript outlines our generalized formulation method using SAP-AA combinations for hydrophobic compounds, and analysis of solubility as a first step towards potential use of these formulations in more functional studies. We include representative solubility results for formulation of the hydrophobic compound, curcumin, and discuss how our methodology serves as a platform for future biological studies and disease models.

This protocol describes a clinically-applicable means of dissolving hydrophobic compounds in an aqueous environment using combinations of self-assembling peptide and amino acid solutions. Our method resolves a major limitation of hydrophobic therapeutics, which lack safe, efficient means of solubility and delivery methods into clinical settings.

自组装肽与氨基酸结合的水溶液中疏水性化合物的溶解度

Self-assembling peptides (SAPs) are promising vehicles for the delivery of hydrophobic therapeutics for clinical applications; their amphipathic ...

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Controlled donation after circulatory death (cDCD) has contributed to increasing donor numbers all over the world. Experiences published in the last years confirm that the outcomes after lung transplantation from cDCD are similar to those from brain death donors; however, the utilization of lungs from asystole donors remains low. Several reasons may be involved: different legal frameworks among countries and centers with different premortem interventions, inadequate lung donor care before procurement, or even poor experience with cDCD procedures and protocols.
Initially, the rapid recovery technique was commonly employed for the procurement of thoracic and abdominal organs in cDCD, but, in the last decade, abdominal normothermic regional perfusion (ANRP) with extracorporeal membrane oxygenation devices has become a useful method to restore blood flow to abdominal organs, allowing their quality improvement and their functional assessment prior to transplantation. This makes the donation procedure more complex and generates doubts about injury to the grafts due to dual temperature.
The aim of this article is to describe a protocol based on a single center experience with Maastricht III donors combining lung cooling rapid recovery in the thorax and abdominal normothermic regional perfusion. Tips and tricks focused on premortem interventions and lung procurement procedure techniques are explained. This may help to minimize the reluctance among professionals to use this combined technique and encourage other donor centers to use it, despite the increased complexity of the procedure.

The protocol combines a lung cooling rapid recovery technique with abdominal normothermic regional perfusion for abdominal graft procurement in controlled asystole donors, which is a safe and useful method to expand the donor pool.

肺快速恢复采购联合腹部正常区域灌注在循环死亡后受控捐献中的应用

Controlled donation after circulatory death (cDCD) has contributed to increasing donor numbers all over the world. Experiences published in the last years ...

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Laparoscopic hepatectomy is a common treatment for colorectal cancer liver metastasis. Previously, a sufficient number of functional liver masses had to be maintained during laparoscopic hepatectomy, with a residual liver volume of &gt;40% in cirrhotic patients and &gt;30% in non-cirrhotic patients. The high incidence of complications such as bleeding, bile leakage, or liver failure due to the exposure and difficulty of the resection of specific liver segments such as S2 and S7 reduces the success rate of liver resection. At present, microwave ablation is mainly applied in the treatment of liver metastasis using a percutaneous approach, which makes it difficult to identify hidden parts or small lesions. For some liver segments, the percutaneous puncture of liver segment 7 (S7) is likely to pass through the thoracic cavity, and the percutaneous puncture of liver segment 2 (S2) adjacent to the diaphragm is likely to injure the diaphragm and heart; these issues restrict the application of percutaneous ablation in colorectal cancer liver metastasis. Considering multiple lesions, laparoscopic microwave ablation combined with hepatectomy was performed in this study. The location of the lesions was determined by contrast-enhanced ultrasound under laparoscopy, and small lesions that were difficult to detect before the operation were identified. For the scattered lesions, which had diameters less than 3 cm and were difficult to resect, ablation was adopted to substitute hepatectomy. This technique helped to more explicitly locate the tumors, simplified the operation procedures, reduced the risk of complications such as bleeding and bile leakage, shortened the operation time, accelerated the postoperative recovery, significantly improved the success rate of operation, and enhanced the clinical prognosis of colorectal cancer liver metastasis by surgical resection.

This protocol describes the laparoscopic resection of colorectal cancer liver metastases combined with ultrasound-guided microwave ablation. This technique can safely, effectively, and accurately treat refractory liver metastases &lt;3 cm, reduce postoperative complications, and accelerate the postoperative rehabilitation of patients.

腹腔镜肝切除术联合术中微波消融术在结直肠癌肝转移中的应用

Laparoscopic hepatectomy is a common treatment for colorectal cancer liver metastasis. Previously, a sufficient number of functional liver masses had to ...

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Here, we describe a protocol to induce switchable in vivo photogeneration of endogenous reactive oxygen species (ROS) in mouse skin. This transient production of ROS in situ efficiently activates cell proliferation in stem cell niches and stimulates tissue regeneration as strongly manifested through the acceleration of burn healing and hair follicle growth processes. The protocol is based on a regulatable photodynamic treatment that treats the tissue with precursors of the endogenous photosensitizer protoporphyrin IX and further irradiates the tissue with red light under tightly controlled physicochemical parameters. Overall, this protocol constitutes an interesting experimental tool to analyze ROS biology.

The aim of this protocol is to induce transient in vivo production of nonlethal levels of reactive oxygen species (ROS) in mouse skin, further promoting physiological responses in the tissue.

通过可切换原卟啉IX依赖性原位活性氧物种光生成刺激小鼠皮肤中的干细胞壁龛和组织再生

Here, we describe a protocol to induce switchable in vivo photogeneration of endogenous reactive oxygen species (ROS) in mouse skin. This transient ...

生物学

<meta charset="utf8"></head><body>使用水杨酸在激光治疗中最大限度地减少色素沉着

Enhancement of Facial Rejuvenation Through a Combination of 1565 nm Non-Ablative Fractional Laser with 30% Supramolecular Salicylic Acid

The 1565 nm non-ablative fractional laser can effectively stimulate collagen regeneration, achieving the effect of skin rejuvenation and anti-aging. In recent years, it has been widely used in dermatology, especially in facial rejuvenation, treatment of stretch marks, and acne scar treatment, with significant results. However, after the 1565 nm non-ablative fractional laser treatment, patients may experience short-term erythema and edema. The inflammation after treatment may also cause pigmentation, making it difficult for some patients to accept. This article introduces a treatment method of 1565 nm non-ablative fractional laser combined with 30% super molecular salicylic acid for facial rejuvenation, effectively reducing posttreatment erythema and post-inflammatory pigmentation. The method includes specific treatment steps and the respective endpoint reactions of each step. The method starts by selecting appropriate energy parameters for the 1565 nm non-ablative fractional laser treatment, followed immediately by the application of 30% supramolecular salicylic acid. The treatment should be stopped when a frosty reaction occurs. The purpose of this project is to provide patients with a safer new method of facial rejuvenation treatment.

<meta charset="utf8"></head><body>作者聚焦:使用激光后水杨酸应用推进面部年轻化疗法

The purpose of this project is to effectively reduce the occurrence of adverse reactions such as erythema and pigmentation after non-ablative fractional laser treatment by combining 1565 non-ablative fractional laser with 30% super molecular salicylic acid, providing patients with a safer new method of facial rejuvenation treatment.

通过 1565 nm 非烧蚀点阵激光与 30% 超分子水杨酸的组合增强面部年轻化

The 1565 nm non-ablative fractional laser can effectively stimulate collagen regeneration, achieving the effect of skin rejuvenation and anti-aging. In ...

滚筒微针联合氨甲环酸溶液治疗黄褐斑

副本

摘要

探索更多视频

突变黑色素细胞干细胞引发小鼠黑色素瘤的时空控制

表皮黑色素和防止晒斑的人性化小鼠模型的诱导药物

肿瘤治疗领域的治疗与联合贝伐单抗治疗复发性胶质母细胞瘤的治疗

治疗SCA1小鼠水溶性化合物，以非特异性升压线粒体功能

自组装肽与氨基酸结合的水溶液中疏水性化合物的溶解度

肺快速恢复采购联合腹部正常区域灌注在循环死亡后受控捐献中的应用

腹腔镜肝切除术联合术中微波消融术在结直肠癌肝转移中的应用

通过可切换原卟啉IX依赖性原位活性氧物种光生成刺激小鼠皮肤中的干细胞壁龛和组织再生

通过 1565 nm 非烧蚀点阵激光与 30% 超分子水杨酸的组合增强面部年轻化

通过 1565 nm 非烧蚀点阵激光与 30% 超分子水杨酸的组合增强面部年轻化